Human schistosomiasis

Bruno Gryseels, Katja Polman, Jan Clerinx, Luc Kestens

Schistosomiasis or bilharzia is a tropical disease caused by worms of the genus *Schistosoma*. The transmission cycle requires contamination of surface water by excreta, specific freshwater snails as intermediate hosts, and human water contact. The main disease-causing species are *S. haematobium*, *S. mansoni*, and *S. japonicum*. According to WHO, 200 million people are infected worldwide, leading to the loss of 1.53 million disability-adjusted life years, although these figures need revision. Schistosomiasis is characterised by focal epidemiology and overdispersed population distribution, with higher infection rates in children than in adults. Complex immune mechanisms lead to the slow acquisition of immune resistance, though innate factors also play a part. Acute schistosomiasis, a feverish syndrome, is mostly seen in travellers after primary infection. Chronic schistosomal disease affects mainly individuals with long-standing infections in poor rural areas. Immunopathological reactions against schistosome eggs trapped in the tissues lead to inflammatory and obstructive disease in the urinary system (*S. haematobium*) or intestinal disease, hepatosplenic inflammation, and liver fibrosis (*S. mansoni*, *S. japonicum*). The diagnostic standard is microscopic demonstration of eggs in the excreta. Praziquantel is the drug treatment of choice. Vaccines are not yet available. Great advances have been made in the control of the disease through population-based chemotherapy but these required political commitment and strong health systems.

Schistosomiasis or bilharzia is a tropical parasitic disease caused by blood-dwelling fluke worms of the genus *Schistosoma*. Adult schistosomes are white or greyish worms of 7–20 mm in length with a cylindrical body that features two terminal suckers, a complex tegument, a blind digestive tract, and reproductive organs. Unlike other trematodes, schistosomes have separate sexes. The male's body forms a groove or gynaecophoric channel, in which it holds the longer and thinner female (figure 1). As permanently embraced couples, the schistosomes live within the perivesical (*Schistosoma haematobium*) or mesenteric (other species) venous plexus. Schistosomes feed on blood and globulins through anaerobic glycolysis. The debris is regurgitated in the host's blood.

The females produce hundreds (African species) to thousands (oriental species) of eggs per day. Each ovum contains a ciliated miracidium larva, which sequesters proteolytic enzymes that help the eggs to migrate into the lumen of the bladder (*S. haematobium*) or the intestine (other species). The eggs are excreted in the urine or feces and can stay viable for up to 7 days. On contact with water, the egg releases the miracidium. It searches for the intermediate host, freshwater snails, guided by light and chemical stimuli. After penetrating the snail, the miracidia multiply asexually into multicellular sporocysts and later into cercarial larvae with embryonic suckers and a characteristic bifurcated tail.

The cercariae start leaving the snail 4–6 weeks after infection and spin around in the water for up to 72 h seeking the skin of a suitable definitive host. Cercarial shedding is provoked by light and occurs mainly during daytime. One snail, infected by one miracidium, can shed thousands of cercariae every day for months. On finding a host, the cercariae penetrate the skin, migrate in the blood via the lungs to the liver, and transform into young worms or schistosomulae. These mature in 4–6 weeks in the portal vein, mate, and migrate to their perivesicular or mesenteric destination where the cycle starts again. The lifespan of an adult schistosome averages 3–5 years but can be as long as 30 years. The theoretical reproduction potential of one schistosome pair is up to 600 billion schistosomes.

The main schistosomes infecting human beings are: *S. mansoni*, which is transmitted by * Biomphalaria* snails and causes intestinal and hepatic schistosomiasis in Africa, the Arabian peninsula, and South America; *S. haematobium*, transmitted by * Bulinus* snails and causing urinary schistosomiasis in Africa and the Arabian peninsula; and *S. japonicum*, transmitted by the amphibian snail *Oncomelania* and causing intestinal and hepatosplenic schistosomiasis in China, the Philippines, and Indonesia (figure 2). *S intercalatum* and *S mekongi* are only of local importance. *S. japonicum* is a zoonotic parasite, which infects a wide range of animals including cattle, dogs, pigs, and rodents. *S. mansoni* is also found in rodents and primates, but human beings are the main host. A dozen other schistosome species are animal parasites, some of which occasionally infect people.

The distribution of the different species depends mainly on the ecology of the snail hosts. Natural streams,
ponds, and lakes are typical sources of infection, but over the past few decades man-made reservoirs and irrigation systems have contributed to the spread of schistosomiasis. The disease is largely a rural problem, but urban foci can be found in many endemic areas.

Snail populations, cercarial density, and patterns of human water contact show strong temporal and spatial variations, resulting in a focal distribution of the infection within countries, regions, and villages (figure 3). Typically, rates and intensities of infection increase from an early age to a peak around age 8–15 years and decrease again in adults. Within populations and age-groups, schistosomes are overdispersed; a small number of individuals carry most of the parasites. These features have been attributed both to water-contact patterns and to innate and acquired immunity. Sex-related patterns vary in relation to behavioural, professional, cultural, and religious factors.

**Acute pathology**

The percutaneous penetration of cercariae can provoke a temporary urticarial rash that sometimes persists for days as papulopurigrinous lesions, especially after primary infections such as occur in tourists and migrants. A similar swimmers’ itch is also frequently caused by cercariae of animal trematodes in temperate climate zones. Possibly, cercarial dermatitis often goes unrecognised in endemic areas.

Acute schistosomiasis (Katayama fever) is a systemic hypersensitivity reaction against the migrating schistosomulae, occurring a few weeks to months after a primary infection. The disease starts suddenly with fever, fatigue, myalgia, malaise, non-productive cough, eosinophilia, and patchy infiltrates on chest radiography. Abdominal symptoms can develop later, caused by the migration and positioning of the mature worms. Most patients recover spontaneously after 2–10 weeks, but some develop persistent and more serious disease with weight loss, dyspnoea, diarrhoea, diffuse abdominal pain, toxaemia, hepatosplenomegaly and widespread rash.

Katayama fever due to *S mansoni* or *S haematobium* is rarely seen in chronically exposed populations, possibly owing to underdiagnosis or in-utero sensitisation. It is common, however, in tourists, travellers, and other people accidentally exposed to transmission. Most cases in western travel clinics are imported from sub-Saharan Africa, many in family or group clusters. Notorious sources of infection are Lake Malawi, Lake Victoria, and Lake Volta, the Zambesi and Niger deltas, and some lake resorts in South Africa. The contacts with infected water include bathing and swimming, scuba diving, water skiing, and rafting.

Katayama fever due to *S japonicum* does also occur in people living in endemic areas and with a history of previous infections. In China, rebound epidemics have been reported in endemic communities exposed to floods. The manifestations can be severe with persistent fever, organomegaly, and cachexia, which can evolve rapidly to hepatosplenic fibrosis and portal hypertension.

**Chronic pathology and morbidity**

The main lesions in established and chronic infection are due not to the adult worms but to eggs that are trapped in the tissues during the perivesical or peri-intestinal migration or after embolisation in the liver, spleen, lungs, or cerebrospinal system. The eggs secrete proteolytic enzymes that provoke typical eosinophilic inflammatory and granulomatous reactions, which are progressively replaced by fibrotic deposits (figure 4).
The severity of the symptoms is thus related both to the intensity of infection and to individual immune responses.

**Urinary schistosomiasis**

The eggs of *S haematobium* provoke granulomatous inflammation, ulceration, and pseudopolyposis of the vesical and ureteral walls. Common early signs include dysuria, pollakiuria, proteinuria, and especially haematuria. In endemic areas, this sign is the red flag of schistosomiasis in children aged 5–10 years, sometimes confused with menstruation in girls and even a coming of age in boys. Typically, blood is first seen in the terminal urine, but in severe cases the whole urine sample can be dark coloured. Bacterial superinfection and bladder stones can complicate the clinical picture. These early signs become less common after adolescence. However, chronic lesions can evolve to fibrosis or calcification of the bladder and lower ureters, resulting in hydroureter and hydronephrosis. Chronic compression can eventually lead to parenchymal damage and kidney failure.

In non-treated populations exposed to *S haematobium*, microhaematuria has been found in 41–100% of infected children, gross haematuria in between none and 97%, and radiologically visible lesions in the upper urinary tract in 2–62%. Kidney function is surprisingly well preserved in many cases. Most lesions, including hydronephrosis, heal well after antischistosomal treatment or even spontaneously, which suggests that the renal parenchyma is compressed but not destroyed in most cases.

Chronic urinary schistosomiasis is epidemiologically associated with squamous bladder cancer in Egypt and other African foci. Nitrosamines, β-glucuronidase, and inflammatory gene damage have been put forward as possible carcinogenic factors. However, an equally likely explanation is that schistosomiasis lesions intensify the exposure of the bladder epithelium to mutagenic substrates from tobacco or chemicals. In Egypt, the incidence of bladder cancer has decreased in line with schistosomiasis prevalence over the past few decades.

Published evidence does not allow deduction of epidemiologically valid rates of mortality directly due to urinary schistosomiasis. Autopsy and clinical observations leave no doubt that patients, particularly older people, die of schistosomiasis-induced renal damage. Other clinical and epidemiological surveys have not shown specific mortality, however.

**Intestinal schistosomiasis**

Schistosome eggs migrating through the intestinal wall provoke mucosal granulomatous inflammation, pseudopolyposis, microulcerations, and superficial bleeding. Most lesions are situated in the large bowel and rectum. The most common symptoms and signs are chronic or intermittent abdominal pain and discomfort,
loss of appetite, and diarrhoea with or without blood. These features are difficult to ascribe unequivocally to schistosomiasis in people with several infections, as is common in endemic areas. Population surveys found that diarrhoea was reported in 3–55% of infected people and bloody diarrhoea in 11–50%, of which 30–60% was attributable to schistosomal infections. The frequency of the symptoms is related to intensity of infection. Field methods and confounding factors vary substantially, however, and the data cannot be easily compared or pooled.

Hepatic schistosomiasis

Hepatic schistosomiasis can be caused by *S mansoni*, *S japonicum*, and *S mekongi*. The pathological effects of *S intercalatum* are limited to mild intestinal disease. The terms hepatic or hepatosplenic schistosomiasis amalgamate early inflammatory and late fibrotic hepatic disease, which are actually two distinct syndromes. The distinction is important not only in clinical practice, but also for morbidity control strategies and the interpretation of immunological mechanisms.

Inflammatory hepatic schistosomiasis is an early reaction to ova trapped in the presinusoidal periportal spaces of the liver; it is the main cause of schistosomal hepatomegaly in children and adolescents. Typical features include sharp-edged enlargement of the left liver lobe and nodular splenomegaly, extending from a few centimetres below the costal arch to below the umbilicus and even into the pelvis. Clinical and epidemiological differentiation from malaria can be difficult. Ultrasonography can reveal mild forms of diffuse fibrosis; in many cases, there is no apparent sign of functional disease. This type of hepatomegaly is found in up to 80% of infected children; it is less common and intense in adults. The frequency and intensity are related to faecal egg counts, but they are also subject to methodological variations, immunogenetic predisposition, and other confounding factors.

Fibrotic or chronic hepatic schistosomiasis develops years later in the course of infection, generally in young and middle-aged adults with long-standing intense infections and, presumably, some form of immunogenetic predisposition. The disease results from a massive deposition of diffuse collagen deposits in the periportal spaces, leading to pathognomonic periportal or Symmer’s pipistem fibrosis. This fibrosis leads in turn to progressive occlusion of the portal veins, portal hypertension, splenomegaly, collateral venous circulation, portocaval shunting, and gastrointestinal varices. The liver is not necessarily enlarged but is generally hard and nodular on palpation. Ultrasonography reveals typical fibrotic streaks and portal-vein dilatation, which are not reversible in most cases. In contrast to cirrhosis, hepatocellular function and indices remain largely unaffected.

Before the advent of modern schistosomicides,
advanced schistosomal liver fibrosis with oesophageal bleeding was a common clinical syndrome in Egypt, Sudan, Brazil, China, and the Philippines but much less frequent in most of sub-Saharan Africa. These regional morbidity patterns have been attributed to ethnic and genetic factors.10

In a heavily infected population in Sudan, the annual mortality due to heavy S. mansoni infection has been estimated at 0.05%, with a case-fatality rate for oesophageal bleeding of 1.1%.11 Clinical studies from other areas with high infection rates also found substantial fatality rates among patients with advanced liver fibrosis.11–13 In most cross-sectional community surveys, however, life-threatening conditions were not detected.13–16 For S. japonicum, the best available data show a case-fatality rate of 1.8% among 278 patients followed up for 12 years in the Philippines.17 High mortality rates have been reported among patients with complicated and even acute schistosomiasis in China, but this evidence is not well documented.18

Ectopic schistosomiasis

Pulmonary schistosomiasis is due to portal-caval shunting, allowing ova to leak into the perialveolar capillary beds. The ensuing granulomas can give rise to bronchial symptoms and later to fibrosis complicated by pulmonary hypertension and cor pulmonale. The symptoms can remain occult for many years.19 In S. mansoni infections, portosystemic leaking of immune complexes to the mesangial areas can lead to glomerulonephritis.63

Genital schistosomiasis, due to eggs of S. haematobium and S. mansoni in the reproductive organs, is quite common but mostly occult in some endemic areas and a regular finding in travellers.64–66 Symptoms in female patients include hypertrophic and ulcerative lesions of the vulva, vagina, and cervix, which might facilitate sexual transmission of infections. Lesions of the ovaries and the fallopian tubes can lead to infertility. In men, the epididymis, testicles, spermatic chord, and prostate can be affected; haemospermia is a common symptom.

Neuroschistosomiasis is caused by inflammation around ectopic worms or eggs in the cerebral or spinal venous plexus, which can evolve to irreversible fibrotic scars if left untreated.66,67 Ectopic S. mansoni and S. haematobium infections seem to cause mainly spinal pathology with transverse myelitis, which is also a potential complication of acute schistosomiasis in travellers.68 S. japonicum is associated with cerebral granulomatous lesions, which can lead to epileptic, paralytic, and meningoencephalitic symptoms.69–72 Sporadically, ectopic schistosomiasis lesions are found in the skin, the peritoneum, or other organs.

Indirect pathology and morbidity

As severe disease becomes less common thanks to modern drugs, subtle or indirect morbidity such as fatigue and physical or cognitive impairment has received more attention. Such unspecific and multifactorial morbidity is difficult to measure and to dissociate from other poverty-related health problems. Older studies could not convincingly demonstrate these effects, even in heavily infected people.73 Recent studies, however, have found small but significant associations between...
Schistosome infection and anaemia, nutritional status, and cognitive and physiological capacities. The underlying mechanisms could range from social determinants to complex immune interactions.

Diagnosis

The microscopic examination of excreta remains the gold standard for the diagnosis of schistosomiasis. The eggs are easy to detect and identify by microscopy owing to their size and shape, their typical lateral or terminal spine, and the living miracidium (in fresh samples) with mobile cilia and pulsing excretory cells (figure 5). Direct wet slides are not very sensitive; if no eggs are found, concentration methods should be used but even these can miss light infections.

Urine should be concentrated by sedimentation, centrifugation, or filtration, and samples should be taken around noon or after physical exercise. To obtain a quantitative assessment of the intensity of infection, a fixed amount (generally 10 mL) of urine is forced over a paper or nitrocellulose filter, which can be examined and eggs counted directly under the microscope. Intensity can then be expressed as eggs per 10 mL.

For the intestinal schistosomes, eggs must be sought in the faeces. Concentration methods, such as sedimentation in a glycerine solution or centrifugation in formalised ether are needed for detection of mild and light infections. In the field, the faecal thick smear or Kato-Katz method is commonly used, because it allows quantification of the infections by egg counts, usually expressed as per g faeces. Rectal snips are very sensitive, even for S. haematobium infection.

Quantitative egg counts after standardised urine filtration or in calibrated faecal thick smears are especially useful for epidemiological surveys and control, since they correlate well with worm burdens and morbidity. Individual egg counts should not be overinterpreted as a measure of disease, however, because they vary substantially within and between stool and urine samples.

Antibody-based assays are quite sensitive but cannot distinguish history of exposure from active infection; they can also cross-react with other helminths and are not easily applicable under field conditions. Such assays are important, however, for diagnosis in travellers, migrants, and other occasionally exposed people. They can also be useful for incidence studies in children and in low-transmission or post-control settings. Most routine techniques detect IgG, IgM, or IgE against soluble worm antigen or crude egg antigen by EIA, indirect haemagglutination, or immunofluorescence. Seroconversion generally happens within 4–8 weeks of infection, but the interval can be as long as 22 weeks. Most assays have positive results for at least 2 years after cure and in many cases much longer.

Somatic schistosome antigens, such as circulating anodic antigen and circulating cathodic antigen, can be detected and quantified with labelled monoclonal antibodies in serum or urine of infected individuals. Antigen detection in serum is not very sensitive in light infections and therefore less useful for clinical applications. However, as a specific, direct, and stable measure of worm burdens, it is a valuable research tool for epidemiological and therapeutic studies. The less specific urine-based antigen detection assays have potential for the development of field-applicable reagent strips.

Reagent strips for microhaematuria and simple questionnaires for red urine are cheap, easy, and effective tools for the screening and rapid epidemiological assessment of urinary schistosomiasis. Such indirect diagnostic methods are less satisfactory for intestinal or hepatic disease. Biochemical markers of pathology are still under investigation.

In hospital settings, cystoscopy and endoscopy are used to visualise bladder lesions and oesophageal varices. Laparoscopy and wedge biopsy can reveal the macroscopic and histological appearance of granulomatous inflammation or periportal fibrosis.

Radiography allows visualisation of renal, ureteral, and bladder pathology. In hepatic schistosomiasis, contrast radiography can show portal-vein distension or gastro-oesophageal varices. CT, myelography, and MRI can be useful for detailed imaging, especially for neuroschistosomiasis. Over the past 10 years, portable ultrasonographic equipment has allowed major
advances in the study of schistosomiasis pathology.\textsuperscript{99} Standard protocols have been developed to classify hepatic fibrosis and urinary-tract lesions. Their use requires specific expertise and experience, however, and is subject to much variation within and between observers.

**Treatment**

Early treatments against schistosomiasis had severe and even lethal side-effects that had to be weighed against the benefits for the patient.\textsuperscript{14} The 1970s heralded the advent of effective, safe, and simple drugs.\textsuperscript{14}

Praziquantel, an acylated quinoline-pyrazine that is active against all schistosome species, is now the most widely used. It is mostly marketed as 600 mg tablets, with a recommended standard regimen of 40 mg/kg bodyweight in a single dose. The drug acts within 1 h of ingestion by paralysing the worms and damaging the tegument. Side-effects are mild and include nausea, vomiting, malaise, and abdominal pain. In heavy infections, acute colic with bloody diarrhoea can occur shortly after treatment, probably provoked by massive worm shifts and antigen release.\textsuperscript{27}

Praziquantel has very low toxicity in animals, and no important long-term safety difficulties have been documented in people so far.\textsuperscript{99} It is judged safe for treatment of young children and pregnant women.\textsuperscript{99}

Praziquantel has little or no effect on eggs and immature worms. Tissue-dwelling eggs can be excreted for several weeks after treatment, and during the same period prepatent or newly acquired infections can become productive. The preferred timing of follow-up is therefore 4–6 weeks after treatment.\textsuperscript{100} After a single dose of 40 mg/kg, 70–100% of patients cease to excrete eggs. In most of those not cured, egg counts and antigen concentrations are reduced by more than 95%.\textsuperscript{99,101,102} Clinical, radiographic, and sonographic studies have shown the regression over weeks to months of intestinal and vesical lesions, reactive hepatomegaly, and even severe lesions of the upper urinary tract or mild liver fibrosis.\textsuperscript{101} This regimen is therefore recommended for most population-based treatment campaigns. In populations with high initial egg counts exposed to rapid reinfection, cure rates can be much lower. In these cases, the dose can be increased to 60 mg/kg, if possible split in two and taken several hours apart to avoid side-effects.\textsuperscript{6,109} 60 mg/kg or more in split doses is also advisable for individual case management or in people who have left the endemic area, to ensure complete cure.\textsuperscript{100} A repeat dose 6–12 weeks later can be useful to cure prepatent infections, particularly if eosinophilia, high antibody titres, or symptoms persist.

Katayama fever is primarily treated with corticosteroids to suppress the hypersensitivity reaction and with praziquantel to eliminate the already matured worms.\textsuperscript{11,18} Since immature worms are not susceptible to praziquantel, treatment should be repeated 4–6 weeks after the first symptoms. In oesophageal bleeding, β blockers, endoscopic sclerotherapy, splenectomy, or a portocaval shunt might be indicated.\textsuperscript{114} In advanced urinary schistosomiasis, damaged and non-functional kidneys might have to be removed.

Corticosteroids and anticonvulsants are needed as possible adjuvants to praziquantel in neuroschistosomiasis, which needs specialised care.\textsuperscript{99} Praziquantel should be administered with great caution in the case of concurrent neurocysticercosis.\textsuperscript{115}

Oxamnique acts only on \textit{S mansoni} and is nowadays mainly used in Brazil.\textsuperscript{115} It is as effective as praziquantel but can provoke more pronounced side-effects, most notably drowsiness, sleep induction, and epileptic seizures.

Artemisinin derivatives are effective against the immature stages of \textit{S japonicum}, \textit{S mansoni}, and possibly \textit{S haematobium}.\textsuperscript{116} Their use in cure or prophylaxis for acute schistosomiasis, possibly in combination with praziquantel, is being investigated.\textsuperscript{116} Widespread use in malaria-endemic areas is not recommended, because it might promote artemisinin resistance in malaria parasites.

A derivative of myrrh (an oleo-resin extract of \textit{Commiphora molmol}; Mirazid; Pharco Pharmaceuticals, Alexandria, Egypt) was heralded as a potent new schistosomicide but appears to be completely ineffective.\textsuperscript{117}

Schistosomes can become resistant to hycanthone and oxamnique, in animals as well as in the field. Resistance to these drugs has never spread beyond local foci, however.\textsuperscript{118} Under drug pressure, praziquantel-tolerant schistosome strains can be quite easily selected in animals.\textsuperscript{119} In the field, very low cure rates have been observed in northern Senegal, but they could be explained by very intense transmission, reinfection, maturing prepatent infections, and possibly the epidemic nature of the focus.\textsuperscript{118} In Egypt, tolerant strains have been isolated from people who did not respond well to treatment, but these observations need to be confirmed.\textsuperscript{118} The catastrophic experience in cattle, with widespread resistance to anthelmintics due to systematic mass treatment, shows that caution is needed.\textsuperscript{118}

**Immunology**

There is longstanding epidemiological and clinical evidence that people living in endemic areas acquire some form of immune resistance after years of exposure.\textsuperscript{114} In terms of parasite population dynamics, host-related factors such as innate or acquired immunity are likely to have an important role in truncating the enormous reproduction potential of schistosomes to the endemic equilibrium of one.\textsuperscript{115} The acquisition of effective immunity is difficult to prove, because the decrease in infection rates after adolescence can also be explained by reduced water contact.

Immunological advances, new epidemiological approaches, and mathematical modelling corroborate
the existence of acquired immunity, however.\textsuperscript{9,113,115} Comparative studies of reinfection after curative treatment have shown that children are far more susceptible than adults and that these differences cannot be explained by differing water-contact patterns. Observations in people and in animals suggest that acquired immunity is mediated by IgE against antigens of larvae and adult worms, which trigger eosinophils to release cytoktoxines targeting schistosomulae.\textsuperscript{116} The slow development of acquired immunity is thought to be due to blockage of the IgE receptors by excess antischistosome IgG, and possibly other immunoglobulin isotypes in the first years of infection. Some researchers suggest a role of schistosome-specific IgA, such as anti-Sm28GST, in mediating protective immunity in people, or of the slow release of somatic antigens of dying worms.\textsuperscript{115,116} The latter hypothesis has been invoked to explain increased immunity after treatment, but other studies did not confirm these observations.\textsuperscript{9,113,115}

In populations with only recent exposure to transmission, age-related infection patterns are surprisingly similar to those in long-standing endemic conditions. Since slowly acquired immunity cannot be invoked in such circumstances, some form of age-related innate resistance could also play an important part in the epidemiology of schistosomiasis.\textsuperscript{119–121}

Most schistosomiasis-related pathology is induced by cellular immune responses. The granulomatous reactions around the eggs are orchestrated by CD4-positive T cells and involve eosinophils, monocytes, and lymphocytes.\textsuperscript{26} In mice, a predominantly T-helper-1 reaction in the early stages of infection shifts to an egg-induced T-helper-2-biased profile, and imbalances between these responses lead to severe lesions.\textsuperscript{122} Although these observations cannot readily be extrapolated, similar mechanisms could be at the basis of fibrotic pathology in human beings.\textsuperscript{46}

Much effort has been devoted to the development of vaccines against schistosomiasis. Several antigens are judged to be potential vaccine candidates and have been tested in animals with varying results.\textsuperscript{123,124} The recombinant rShGST-28 (Billhavx; Eurogentec, Herstal, Belgium) has already undergone phase I and II clinical trials.\textsuperscript{118} Questions remain about the feasibility, applicability, and relevance of schistosomiasis vaccines, however.\textsuperscript{123,124}

The possible interaction between schistosomiasis and HIV/AIDS is receiving increasing attention, given the role of immune responses in both diseases and the geographic overlap in distribution in Africa.\textsuperscript{2} Low CD4-positive T-cell counts resulting from HIV infection might increase susceptibility to schistosome infection and influence egg excretion.\textsuperscript{125,126} HIV infection would not affect the efficacy of praziquantel, susceptibility to reinfection, the development of fibrosis, or the diagnosis and surveillance of schistosomiasis.\textsuperscript{123–126} Conversely, schistosomiasis does not interfere with HIV screening or viral-load testing and should not exacerbate the course of HIV infection, but it might contribute to immune reconstitution syndromes after antiretroviral treatment.\textsuperscript{129} Schistosomiasis treatment can result in lower viral loads and higher CD4-cell counts.\textsuperscript{113,115} The clinical and epidemiological significance of all these observations is still unclear.

Global burden

Schistosomiasis is highly prevalent, but the associated morbidity is low and variable. Thus, its influence on public health and the priority of control measures have long been debated. The discussion has been revived in light of the renewed resources for the fight against poverty-related diseases and the Global Burden of Disease Study, which attempted to quantify and rank health problems according to disability-adjusted life years (DALY).\textsuperscript{111} This index is calculated from disease-specific prevalence, mortality, and disability weights. The Global Burden of Disease Study currently attributes a disability weight of 0·06 and an annual mortality of 14000 deaths per year to schistosomiasis. Based on the generally accepted number of 200 million infected people worldwide, the total number of DALY lost to schistosomiasis is estimated at 1·532 million per year, of which 77% are in sub-Saharan Africa. Schistosomiasis would therefore account for 0·1% of the total world global burden of disease and 0·4% of that in sub-Saharan Africa, which is of the same order as leishmaniasis and trypansomiasis. New meta-analyses of existing data have resulted in proposals to increase the schistosomiasis disability weight by a factor of between three and 30, and the mortality estimate up to 280 000 deaths annually in sub-Saharan Africa alone.\textsuperscript{9,113,114}

Both the Global Burden of Disease Study and the revisions are, however, limited by the lack of representative data and of clear case definitions. Where they have been adequately measured, true national prevalences are three to ten times lower than the WHO estimates that extrapolated local surveys without accounting for geographic heterogeneity.\textsuperscript{115–140} By contrast, with standard survey methods true prevalence can be underestimated by 50% or more.\textsuperscript{27} The proposed revision of the mortality rates relies on similar overestimates and would add an unexplained 10% to overall mortality in male adults in sub-Saharan Africa.\textsuperscript{114} The proposed revision of the disability weight is based on a thorough meta-analysis of published morbidity data; however, owing to the differing methods and confounding factors, these cannot readily be pooled to extract precise disability weights.\textsuperscript{46} New, dedicated field studies would be needed to validate the proposed changes.

Control

The aims and strategies of schistosomiasis control have shifted fundamentally over the past few decades, since the introduction of modern schistosomicides, particularly praziquantel. As for other parasitic diseases, transmission control aiming at the intermediate host has been largely replaced by morbidity control through population-based chemotherapy. This strategy allows quick gains, but
careful long-term planning is needed to ensure sustainability and progression to the more demanding stages of infection and transmission control.

Snail control with mollusicides, toxic chemicals, is expensive and logistically complex. Substantial human and material resources are needed for efficient application, as well as detailed epidemiological and malacological surveillance. Snail populations can be greatly reduced but rarely eliminated, so regular and long-term retreatment is necessary. The toxicity of mollusicides for other aquatic organisms, including fish, gives rise to ecological and economic concerns. Large-scale chemical snail control is still used in Egypt and China, but owing to the success of population-based chemotherapy, its cost-effectiveness is increasingly being questioned. Snail control can also be pursued by physical measures or biological competitors, but such methods are not easy to put into practice.

Schistosomiasis can in principle be eliminated by behavioural changes, sanitation, and safe water supply, as has been shown in Japan. Educational programmes can improve knowledge about the disease and health-care seeking, but behaviour can be difficult to change without other options for water contact. The provision of safe water supplies and latrines is obviously useful, but for the prevention of schistosomiasis, safe contact sites are also needed. In the case of *S japonicum*, transmission control necessitates interventions on the large and diverse animal reservoir.

On the recommendation of WHO, population-based treatment with praziquantel is now the main component of most national control programmes. The fundamental aim is to reduce morbidity by keeping down intensity of infection. Various strategies can be applied, including indiscriminate mass treatment, active case finding, and treatment of particular risk groups such as school-aged children. 20 years of experience have shown that population-based treatment is feasible, safe, and effective. In the absence of ecological or behavioural changes, however, it has little durable effect on transmission; regular retreatment is therefore needed for an unknown period. Sustainability is therefore a key requirement for chemotherapy-based control.

Wide-scale chemotherapy has greatly reduced the public-health impact of schistosomiasis in middle-income countries such as Egypt, China, Brazil, the Philippines, Puerto Rico, Tunisia, Morocco, and Saudi Arabia. Key factors to success were national commitment and investments, in several cases through loans from the World Bank, implementation through regular health services, and concurrent socioeconomic development. The challenge for these countries is now to move towards control and possibly elimination of infection and transmission. The main technical difficulty lies in identification of remaining cases and pockets through an integrated surveillance and response system. The progressive elimination of transmission sources requires intensive intersectoral collaboration, and political commitment might wane as morbidity decreases. Also the liberalisation of health care could be a threat to control programmes for schistosomiasis and other diseases. In China, market reforms might already have led to the re-emergence of schistosomiasis in some areas.

Low-income countries, especially those in sub-Saharan Africa, have had greater difficulties in implementing and sustaining chemotherapy-based control strategies. Early pilot projects in Mali, Congo, Madagascar, and Malawi showed promising results in the short term but floundered when foreign assistance ended. Other programmes were built up more gradually, by improving passive or active case finding through regular health-care structures. Although less spectacularly successful in the short term, they appeared to be sustainable with limited national resources.

Renewed efforts are now being made to extend chemotherapy-based control of schistosomiasis to sub-Saharan Africa and to integrate these efforts with systematic anthelmintic treatment in school-aged children. The main vehicles are the Schistosomiasis Control Initiative and the Partners for Parasite Control Consortium, public-private partnerships supported by the Bill and Melinda Gates foundation, drug-donating companies, WHO, and academic institutes. Following a resolution by the World Health Assembly, they have set a joint global target to provide annual preventive treatment to at least 75% of all school-aged children at risk of morbidity from schistosomiasis or soil-transmitted helminths by the year 2010. The programme is by now active in Burkina Faso, Mali, Niger, Tanzania, Uganda, and Zambia. Proposals are being developed for a further integration with drug-delivery programmes for lymphatic filariasis, onchocerciasis, and nutritional deficiencies in a single package and to link these programmes with those against AIDS, malaria, and tuberculosis. Another integration challenge lies, however, with the health workers in the field, who must cope with a wide variety of vertical programmes in their daily routine. For many, provision of accessible care for people with symptoms will be the first step in a strategy of morbidity control.

The way forward

In theory, doctors and other health workers have adequate tools at hand for diagnosis and treatment of most overt cases of schistosomiasis in outpatient or primary care. However, detection of light infections and assessment of their clinical importance remains more difficult. Resistance to praziquantel should be avoided at all costs, and new drugs would be welcome. Improved diagnostic agents and therapeutic strategies are therefore main topics for further applied research on schistosomiasis. A truly evidence-based consensus should be built on how to assess and use the available data on disease burden not just at the global level, but also at national and local levels.

Scientists and funding agencies should also pursue
more vigorously hypothesis-driven research on the biology, epidemiology, and immunology of schistosomiasis. The relation between human beings and schistosomes remains one of the most baffling tricks of nature; its elucidation could teach us much about both species.

Enormous progress has been made in the control of schistosomiasis in many countries. Extension of these successes to countries with fewer resources, in particular sub-Saharan Africa, is imperative, but the lessons of the past should not be forgotten. The fight against schistosomiasis is not just a matter of distributing drugs; establishment of strong health systems that are able to take care of patients and to integrate sustainable control measures is a far greater and more important challenge. A definitive solution to the schistosomiasis problem, finally, can be achieved only by eliminating its main underlying cause—poverty.

Contributors
Bruno Gryseels wrote the initial drafts and the final paper. Katja Polman contributed to the sections on biology and epidemiology, diagnosis, and treatment and control. Jan Clerinx contributed to the section on pathology. Luc Kestens contributed to the section on immunology. All authors contributed to overall revisions and final editing.

Conflict of interest
We declare that we have no conflict of interest.

Acknowledgments
We dedicate this Seminar to Dr Peter (Pip) Jordan, who died on May 30, 2006. He was a great schistosomiasis expert, who made fundamental contributions to the successful control of this disease in large parts of the world. We thank Kristien Wyants for secretarial assistance, contributions to the initial phase of schistosomiasis mansoni. Ann Trop Med Parasitol 1995; 89: 271–78.

We thank the Institute of Tropical Institute of Antwerp, Jean-Pierre Wenseleers for the graphic work. The work on this seminar was solely funded by the Institute of Tropical Institute of Antwerp.

References
25 Ross AG, Sleigh AC, Jobin WR. Health and irrigation. ILRI project.
39 Fine J. Hydronephrosis in a series of 1,400 post-mortem


58 De Vlas SJ, Gryseels B, van Oortmarssen GJ, Polderman AM. Severe hepatic fibrosis in Schistosoma mansoni infection who were followed up for two years after treatment. Clin Infect Dis 1997; 24: 304–08.


130 Fernando R, Miller R. Immune reconstitution eosinophilia due to schistosomiasis. Sex Transm Infect 2002; 78: 76.


